MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In Vivo

Daniel J. Lips, BS; Orlando F. Bueno, MD, PhD; Benjamin J. Wilkins, BS; Nicole H. Purcell, PhD; Robert A. Kaiser, PhD; John N. Lorenz, PhD; Laure Voisin, PhD; Marc K. Saba-El-Leil, PhD; Sylvain Meloche, PhD; Jacques Pouysségur, PhD; Gilles Pagès, PhD; Leon J. De Windt, PhD; Pieter A. Doevendans, MD; Jeffery D. Molkentin, PhD

Background—Myocardial infarction causes a rapid and largely irreversible loss of cardiac myocytes that can lead to sudden death, ventricular dilation, and heart failure. Members of the mitogen-activated protein kinase (MAPK) signaling cascade have been implicated as important effectors of cardiac myocyte cell death in response to diverse stimuli, including ischemia-reperfusion injury. Specifically, activation of the extracellular signal–regulated kinases 1/2 (ERK1/2) has been associated with cardioprotection, likely through antagonism of apoptotic regulatory pathways.

Methods and Results—To establish a causal relationship between ERK1/2 signaling and cardioprotection, we analyzed Erk1 nullizygous gene-targeted mice, Erk2 heterozygous gene-targeted mice, and transgenic mice with activated MEK1-ERK1/2 signaling in the heart. Although MEK1 transgenic mice were largely resistant to ischemia-reperfusion injury, Erk2+/− gene-targeted mice showed enhanced infarction areas, DNA laddering, and terminal deoxynucleotidyl transferase–mediated dUTP biotin nick-end labeling (TUNEL) compared with littermate controls. In contrast, enhanced MEK1-ERK1/2 signaling protected hearts from DNA laddering, TUNEL, and preserved hemodynamic function assessed by pressure-volume loop recordings after ischemia-reperfusion injury.

Conclusions—These data are the first to demonstrate that ERK2 signaling is required to protect the myocardium from ischemia-reperfusion injury in vivo. (Circulation. 2004;109:1938-1941.)

Key Words: ischemia • cardiac output • mitogen-activated protein kinases • infarction • signal transduction

The mitogen-activated protein kinases (MAPK) constitute an essential signal transduction cascade that occupies a central position in cell growth, differentiation, apoptosis, and transformation. Although it is somewhat oversimplified, the MAPK signaling pathway consists of a sequence of successively acting kinases that ultimately result in the dual phosphorylation and activation of the terminal kinases p38, c-Jun N-terminal kinase (JNKs), and extracellular signal–regulated kinase (ERKs). The MAPK signaling cascade is initiated in cardiac myocytes by G-protein–coupled receptors, receptor tyrosine kinases, cardiotrophin-1 (gp130 receptor), and stress stimuli. The major upstream activators of ERK1/2 are 2 MAP kinase kinases (MAPKK), MEK1 and MEK2, which directly phosphorylate the dual site on ERK kinases (Thr-Glu-Tyr).

Within the heart, members of the MAPK cascade have been implicated in regulating myocyte survival after ischemia-reperfusion injury, oxidative stress, and anthracycline exposure. Indeed, a number of studies support the hypothesis that the MEK1-ERK1/2 branch of the MAPK pathway is cardioprotective by directly antagonizing myocyte apoptosis. Although MEK1-ERK1/2 signaling is thought to protect the myocardium from apoptotic insults, definitive genetic data demonstrating a necessary function for this pathway in vivo have not been reported.

Methods

Murine In Vivo Ischemia-Reperfusion and Pressure-Volume Acquisition

Adult mice (aged 8 to 10 weeks) were anesthetized, placed on a heating plate, and ventilated (250 μL; 200 strokes per minute). A left thoracotomy was performed, and the left anterior descending artery was ligated with 8-0 Prolene with a slipknot, which was subsequently removed 60 or 90 minutes later to allow reperfusion for 4 hours, 24 hours, or 7 days. To assess physiological function, a 1.4F conductance micromanometer was inserted through the right common carotid artery and into the left ventricle in mice 7 days after

Received August 22, 2003; de novo received December 22, 2003; revision received March 15, 2004; accepted March 15, 2004.

From the Department of Cardiology, Maastricht University, and Heart Lung Center Utrecht, Maastricht and Utrecht, Netherlands (D.J.L., L.J.D., P.A.D.); Departments of Pediatrics (O.F.B., B.J.W., N.H.P., R.A.K., I.D.M.) and Physiology (J.N.L.), University of Cincinnati, Children’s Hospital Medical Center, Cincinnati, Ohio; Institut de recherches cliniques de Montréal, Departments of Pharmacology and Molecular Biology, Université de Montréal, Montréal, Quebec, Canada (L.V., M.K.S., S.M.); and Department of Developmental Biology and Cancer Research, Institute of Signaling, Centre Antoine Lacassagne, Nice, France (J.P., G.P.).

Correspondence to Jeffery D. Molkentin, PhD, Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children’s Hospital Medical Center, 3333 Burnet Ave MLC7020, Cincinnati, OH 45229-3039. E-mail jeff.molkentin@cchmc.org

© 2004 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

DOI: 10.1161/01.CIR.0000127126.73759.23

1938
ischemic injury. Infarct size and area at risk were determined 24 hours after ischemic injury by ligating the left anterior descending artery and infusing 300 μL of 2% Evans blue dye, followed by staining heart cross sections in 2% 3,3′-triphenyltetrazolium chloride (TTC) solution at 37°C.

**Biochemical and Molecular Analyses**

Wild-type, Erk1−/−, and Erk2−/− mice were either injected subcutaneously with 10 mg/kg phenylephrine or PBS vehicle or subjected to 30 minutes of ischemia. Hearts were later harvested for Western blotting or ERK immunoprecipitation kinase assay as previously described with a rabbit polyclonal ERK1/2 antibody (cell signaling blotting or ERK immunoprecipitation kinase assay as previously described). 30 minutes of ischemia. Hearts were later harvested for Western blotting or ERK immunoprecipitation kinase assay as previously described with a rabbit polyclonal ERK1/2 antibody (cell signaling blotting or ERK immunoprecipitation kinase assay as previously described). With Susceptibility to Ischemic Damage

**Genetic Alterations in ERK Activity Correlate With Susceptibility to Ischemic Damage**

Although most studies using cell culture–based models have suggested an antiapoptotic role for ERK signaling, such conclusions have yet to be definitively extended to an intact animal. In the present study, Erk1−/− and Erk2−/− gene-targeted mice underwent 60 minutes of left ventricular cardiac ischemia followed by 24 hours of reperfusion to induce myocardial infarctions and cell death in vivo. Remarkably, Erk2−/− mice (C57Bl/6) showed a significant increase in total left ventricular infarct area (normalized to area at risk) compared with strain-matched wild-type controls (C57Bl/6) (P<0.05)(Figure 1E, 1F). No significant differences were observed in the area at risk normalized to left ventricular area (data not shown). Loss of Erk1 did not significantly enhance myocardial infarction susceptibility (see Discussion). To extend the mechanistic implications of these observations,
transgenic mice expressing an activated MEK1 mutant protein in the heart were analyzed (gain of function for ERK1/2 signaling). MEK1 transgenic mice were significantly protected from ischemia-reperfusion injury (Figure 1E, 1F).

**Assessment of Physiological Function**

Each cohort was analyzed 7 days after ischemic injury by invasive hemodynamics of left ventricular pressure-volume loops collected in the anesthetized mouse. After 90 minutes of ischemic injury, wild-type FVB/N mice demonstrated a significant decrease in cardiac output and ejection fraction and deterioration in the pressure-volume relationship ($P<0.05$) (Figure 2A, 2B). In dramatic contrast, MEK1 transgenic mice (FVB/N) did not show a significant loss in functional performance or the rightward shift in the pressure-volume relationship during either diastole or systole (Figure 2A, 2B). Erk1$^{-/-}$ and Erk2$^{+/+}$ gene-targeted mice were also analyzed after ischemia-reperfusion injury and compared with Bl/6sv129 or C57Bl/6 strain-matched controls, respectively. In this series of experiments, slightly less injury was suggested by expression of activated MEK1 (Figure 2E). More importantly, inhibition of endogenous ERK1/2 activity with MKP-3 noticeably enhanced staurosporine-induced DNA laddering in MEK1 transgenic hearts compared with strain-matched controls ($P<0.05$ and significantly higher TUNEL and DNA laddering in Erk2$^{+/+}$ hearts compared with strain-matched controls ($P<0.05$) (Figure 2C, 2D). These results were extended through the use of neonatal myocytes infected with recombinant adeno/vectors expressing various MEK1-ERK1/2 effectors, which were subsequently treated with staurosporine (500 nmol/L) for 18 hours to induce apoptosis. Staurosporine induced significant DNA laddering in control Adβgal-infected myocytes, which was qualitatively antagonized by expression of activated MEK1 (Figure 2E). More importantly, inhibition of endogenous ERK1/2 activity with recombinant adeno/vectors expressing either dominant negative MEK1 or the ERK-specific dual-specificity phosphatase MKP-3 noticeably enhanced staurosporine-induced DNA laddering (Figure 2E).

**Discussion**

Although previous studies have suggested the hypothesis that ERK activation can partially antagonize apoptosis, some disagreement persists in the literature concerning the role of ERK signaling in regulating apoptosis. Furthermore, most previous studies relied solely on cultured cardiomyocytes to mechanistically assess the importance of ERK signaling in regulating cardiomyocyte viability after an apoptotic insult. In the present study, we used genetically altered mouse models with both enhanced and depressed ERK signaling in vivo to establish a direct relationship between this signaling pathway and susceptibility to ischemia-reperfusion injury.

An interesting aspect of the present study is that Erk2 heterozygote gene-targeted mice showed enhanced myocardial injury after ischemia-reperfusion stimulation, whereas...
Erk1-null mice showed a level of injury equivalent to that in wild-type mice. This differential susceptibility to ischemia-reperfusion injury documented between Erk1-null and Erk2 heterozygote gene-targeted mice suggests 2 possible mechanisms. Quantitative Western blotting indicated that ERK2 protein levels are higher than ERK1, as shown in certain other cell types. However, Erk2 heterozygote mice showed somewhat similar reduction in total kinase activity in the heart after acute ischemia or phenylephrine injection compared with Erk1-null mice (Figure 1C and 1D). Thus, the loss of 1 allele of Erk2 appears to alter the net amount of ERK1/2 activity in the heart, similar to the result with loss of both Erk1 alleles. Another more plausible mechanism is that ERK1 and ERK2 have specific functions, as suggested by the lack of compensation by Erk1 in Erk2-null mice, the latter of which die during embryonic development.

A number of downstream ERK effectors have been identified that could explain, in part, their antiapoptotic regulatory function. For example, ERK1/2 can directly phosphorylate and activate p90rsk, which in turn phosphorylates the proapoptotic factor Bad in the mitochondria, resulting in cellular protection. ERK factors were also shown recently to interact with PKCe within the mitochondria, facilitating cellular protection within the context of the intact heart. Although numerous downstream mechanisms are likely involved, the present report is the first to genetically demonstrate that MEK1-ERK2 signaling protects the heart from apoptotic insults in vivo. A future challenge will be to develop strategies that exploit this function of the ERK1/2 signaling pathway in the heart by tightly controlling activation to potentially benefit the myocardium during stress.

**Acknowledgments**

This study was supported by the National Institutes of Health and an American Heart Association Established Investigator Grant to Dr Molkentin. We thank the Hein J.J. Wellens Foundation of the Netherlands for research support to Dr Lips.

**References**

MEK1-ERK2 Signaling Pathway Protects Myocardium From Ischemic Injury In Vivo
Daniel J. Lips, Orlando F. Bueno, Benjamin J. Wilkins, Nicole H. Purcell, Robert A. Kaiser,
John N. Lorenz, Laure Voisin, Marc K. Saba-El-Leil, Sylvain Meloche, Jacques Pouysségur,
Gilles Pagès, Leon J. De Windt, Pieter A. Doevendans and Jeffery D. Molkentin

Circulation. 2004;109:1938-1941; originally published online April 19, 2004;
doi: 10.1161/01.CIR.0000127126.73759.23
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/109/16/1938

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/